Crossmark

A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC)

Crossref DOI link: https://doi.org/10.1186/s13048-025-01924-8

Published Online: 2025-12-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Li

Xie, Lingling

Li, Qingshui

Shen, Yang

Wang, Huaying

Sun, Li

Yang, Hongying

Cao, Dongyan

Li, Haiying

Lin, Bei

Chen, Qionghua

Guo, Ruixia

Lou, Ge

Liu, Ziling

Shen, Yuanming

Feng, Weiwei

Zhang, Ping

Zhou, Jianwei

Wang, Xipeng

Wang, Yue

Shen, Zhen

Xue, Fengxia

Ma, Liguo

Tu, Chunhua

Yang, Yingjie

Cheng, Wenjun

Zhang, Yi

Kang, Shan

Li, Congzhu

Wen, Hongwu

Wu, Xin

Luo, Xiping

Yin, Rutie https://orcid.org/0000-0002-9221-6727
Lin, Zhongqiu https://orcid.org/0000-0002-9891-2854
License Information

Text and Data Mining valid from 2025-12-17

Version of Record valid from 2026-01-26
More Information

Article History

Received: 12 August 2025

Accepted: 27 November 2025

First Online: 17 December 2025

Declarations

:

: The protocol and any amendments thereof were reviewed and approved by the Ethics Committees of participating sites (2020-KY-039). All patients provided written informed consent prior to enrolment and patient information was kept under relevant data protection and privacy legislation.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below